24/7 Wall St.10h
Billionaire Healthcare Investor Alex Denner’s Hedge Fund Has 75% of Its Assets in These 3 Stocks
If you work in the biotech industry, you might know the name Alex Denner. If not, his name probably doesn’t ring a bell. ...
Robinhood, Home Depot, and More Stocks for the ‘Silver Tsunami’ of Older Shoppers
People who are 75 and older will compose 10% of the total population in the U.S. by 2030, representing a 7.5% increase from ...
Biogen call volume above normal and directionally bullish
Bullish option flow detected in Biogen (BIIB) with 2,556 calls trading, 1.5x expected, and implied vol increasing over 1 point to 34.69%.
Medindia17h
SKYCLARYS (omaveloxolone) Approval by Health Canada Ushers in a New Era for Friedreich's Ataxia Treatment in Canada
As the only approved treatment to address disease progression, SKYCLARYS addresses a long-standing gap in the care of Canadians living with Friedreich's ataxia Friedreich's ...
Le Lézard18h
SKYCLARYStm (omaveloxolone) Approval by Health Canada Ushers in a New Era for Friedreich's Ataxia Treatment in Canada
Biogen Canada Inc. is pleased to announce that Health Canada has approved SKYCLARYStm (omaveloxolone) for the treatment of Friedreich's ataxia (FA) in patients 16 years of age and older.2 This ...
Biogen VP to Keynote 2025 Bioelectronic Medicine Forum in NYC
Neurotech Reports, the publisher of the Neurotech Business Report and BioElectRx Business Report newsletters, announced that ...
SKYCLARYS™ (omaveloxolone) Approval by Health Canada Ushers in a New Era for Friedreich's Ataxia Treatment in Canada
Biogen Canada Inc. is pleased to announce that Health Canada has approved SKYCLARYS™ (omaveloxolone) for the treatment of Friedreich's ataxia (FA) in patients 16 years of age and older.2 This approval ...